Exploring direct and indirect targets of current antileishmanial drugs using a novel thermal proteomics profiling

Ana Victoria Ibarra-Meneses1,2, Audrey Corbeil1,2, Victoria Wagner1,2

  • 1Département de Pathologie et Microbiologie, Faculté de Médecine Vétérinaire, Université de Montréal, Saint-Hyacinthe, QC, Canada.

Insights

Thermal proteome profiling identified new drug targets and resistance mechanisms in Leishmania infantum, crucial for developing novel treatments against visceral leishmaniasis (VL). This approach aids in understanding and combating drug resistance in this fatal neglected tropical disease.

Area of Science:

  • Parasitology and Tropical Diseases
  • Molecular Biology and Proteomics
  • Drug Discovery and Pharmacology

Background:

  • Visceral leishmaniasis (VL), caused by Leishmania infantum, is a fatal neglected tropical disease with limited treatment options.
  • Current chemotherapy relies on drugs like antimony, miltefosine, and amphotericin B, but widespread drug resistance is a growing concern.
  • Lack of molecular markers for resistance necessitates innovative methods to identify drug targets and resistance mechanisms.

Purpose of the Study:

  • To characterize the mode of action of antileishmanial drugs (antimony, miltefosine, amphotericin B).
  • To understand the mechanisms of drug resistance in Leishmania parasites.
  • To identify novel drug targets and proteins involved in antileishmanial drug resistance.

Main Methods:

  • Implementation of thermal proteome profiling (TPP), a novel approach utilizing multiplexed quantitative mass spectrometry-based proteomics.
  • Monitoring protein melting profiles in wild-type and drug-resistant Leishmania infantum strains in the presence and absence of antileishmanial drugs.
  • Bioinformatics analysis including data normalization, melting profile fitting, and identification of drug-protein interactions and resistance-associated proteins.

Main Results:

  • TPP successfully narrowed down proteome regions interacting with antimony, miltefosine, and amphotericin B, validating known and uncovering novel drug targets.
  • Candidate proteins potentially involved in drug resistance mechanisms were identified.
  • Thermal proximity coaggregation analysis highlighted the importance of specific metabolic pathways, such as those involving tryparedoxin peroxidase and aspartate aminotransferase, in antimony response.

Conclusions:

  • The study provides a valuable platform for identifying antileishmanial drug targets and understanding resistance mechanisms.
  • Results pave the way for developing innovative diagnostic tools for antimicrobial-resistant Leishmania populations.
  • The findings open avenues for the development of new on-target therapies to combat visceral leishmaniasis.